Ipamorelin
Also known as: NNC 26-0161
A selective growth hormone secretagogue with minimal side effects.
Overview
Ipamorelin is a pentapeptide growth hormone secretagogue that stimulates GH release from the pituitary with high selectivity. Unlike other GHRPs, it does not significantly affect cortisol or prolactin levels.
Mechanism of Action
Binds to ghrelin/GHS receptors in the pituitary, triggering GH release. Does not affect ACTH, cortisol, or prolactin secretion, making it highly selective for GH pathway.
Pharmacokinetics
Peak GH release 30-40 minutes post-injection. Half-life approximately 2 hours. Effects last 3-4 hours.
Dosing Protocols
Note: These are research protocols from literature. This is not medical advice.
Standard
200-300 mcg
1-3x daily
8-12 weeks
Before bed and/or post-workout
Anti-Aging
100-200 mcg
Once daily at bedtime
Ongoing
Lower maintenance dose
Stacking Recommendations
Peptides that may be combined based on complementary mechanisms in research settings.
Research Areas
Key Research Findings
- 1Dose-dependent GH release without cortisol or prolactin increase
- 2Improved body composition in clinical studies
- 3Enhanced sleep quality and recovery
- 4Favorable safety profile compared to other secretagogues
Side Effects & Contraindications
Reported Side Effects
- Headache
- Flushing
- Dizziness (rare)
Contraindications
- Active malignancy
- Pregnancy
Safety Considerations
Well-tolerated with minimal side effects. No significant impact on glucose metabolism at standard doses.
Storage Requirements
Store lyophilized at -20C. Reconstituted stable at 2-8C for 30 days.
Scientific References
- 1Ipamorelin, a new growth-hormone-releasing peptide
Raun K, et al.
European Journal of Endocrinology, 1998